Medical Device Electronic Labeling Act
The Medical Device Electronic Labeling Act would amend the Federal Food, Drug, and Cosmetic Act to allow required labeling for certain medical devices to be provided solely by electronic means. The bill applies to devices, including in vitro diagnostic devices, and requires manufacturers to give intended users easy, user-friendly access to the labeling, provide a mechanism to request paper copies at no additional cost, and ensure the device or its immediate container still bears required label information. It also authorizes the Secretary of Health and Human Services, through FDA, to issue orders adding requirements or creating exceptions where needed for safety, effectiveness, or patient-use concerns.
In addition to changing the labeling rule itself, the bill directs FDA to publish a request for information and open a public docket within two years of enactment to gather stakeholder input on how to improve the format, accessibility, and usability of electronic labeling for certain devices. The measure is aimed at modernizing device labeling practices while preserving access to paper copies and allowing FDA to tailor requirements for devices used without provider supervision or where electronic-only labeling may not be sufficient.
The bill would amend Section 502(f) of the Federal Food, Drug, and Cosmetic Act, creating a new federal framework that permits electronic-only labeling for a broader set of medical devices and in vitro diagnostics. It would affect device manufacturers, FDA regulators, health care providers, and end users by shifting labeling compliance toward digital access while preserving paper-copy rights and FDA oversight through order-making authority. The bill would also require FDA to engage in a public comment process on electronic labeling usability and accessibility, potentially influencing future regulations and guidance.
There is no recorded committee debate or vote history in the provided materials, so the bill’s sentiment cannot be measured from formal discussion. Based on the text and sponsorship, the bill appears to be a modernization and efficiency measure with a consumer-protection backstop, suggesting likely support from stakeholders interested in digital access and regulatory flexibility. At the same time, the built-in FDA authority to impose additional requirements indicates awareness of safety concerns and a desire to balance innovation with oversight.
The main points of contention would likely center on whether electronic-only labeling is sufficiently accessible and reliable for all users, especially patients using devices without provider supervision and users who may have limited internet access or digital literacy. Another likely issue is whether the FDA should have broad discretion to add requirements or carve out exceptions by order, which could be viewed as necessary flexibility by supporters but as regulatory uncertainty by critics. Manufacturers may favor reduced paper-labeling burdens, while patient advocates and some providers may emphasize the need for clear, durable, and easily retrievable labeling information.